Progressive loss of vision caused by asymptomatic pituitary macroadenoma: role of OCT.
BACKGROUND
Most pituitary adenomas are clinically inactive. In patients with long-standing compression of the optic chiasm, ganglion cells may undergo axonal degeneration. Spectral domain optical coherence tomography (SD-OCT) is able to identify retinal nerve fiber layer (RNFL) and ganglion cell loss in the retina. We present a case in which SD-OCT was used to diagnose an asymptomatic pituitary macroadenoma.


METHODS
A 48-year-old female presented with progressive vision loss in both eyes. SD-OCT identified atrophy of the ganglion cell and nerve layers, with preservation of outer layers bilaterally. Magnetic resonance imaging of the brain showed a pituitary macroadenoma. The pathological diagnosis was nonfunctioning adenoma.


CONCLUSIONS
As macroadenomas enlarge, they can induce uncrossed axon loss, resulting in nasal field defects and reduced visual acuity. In these cases, there is atrophy of the nasal and temporal portions of the optic disc, thus occupying a horizontal band across the disc. SD-OCT is able to identify RNFL loss in eyes with band atrophy of the optic nerve, which correlates with visual field defects found in perimetry. SD-OCT is a useful tool to assess the structural and functional damage of ganglion cells. In our case the SD-OCT demonstrated a symmetrical loss of the RNFL and the ganglion cell layer in both eyes, indicating important optic nerve damage.
Ophthalmology Department, Clinical University Hospital of Valladolid, Valladolid, Spain.
Víctor Manuel
VM
Asensio-Sánchez
Ophthalmology Department, Clinical University Hospital of Valladolid, Valladolid, Spain.
Javier
J
Foncubierta
OCT; RNFL; adenoma; ganglion cell layer; pituitary
Ophthalmology. 2004 Dec;111(12):2278-83
15582087
Br J Ophthalmol. 2004 Jul;88(7):896-9
15205233
Am J Ophthalmol. 2009 Jan;147(1):64-70.e2
18774545
J Clin Endocrinol Metab. 2011 Apr;96(4):905-12
21474687
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):525-41
19945021
Acta Ophthalmol. 2009 Nov;87(7):776-9
18771481
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4827-35
17065494
Cancer. 2004 Aug 1;101(3):613-9
15274075
Curr Opin Ophthalmol. 2003 Dec;14(6):325-31
14615635
Ann Intern Med. 1994 May 15;120(10):817-20
8154641
Ann Endocrinol (Paris). 2015 Jul;76(3):210-9
26070465
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60
22863387
World Neurosurg. 2011 Jul-Aug;76(1-2):141-8; discussion 63-6
21839965
Invest Ophthalmol Vis Sci. 2011 Oct 31;52(11):8527-33
21960556
Arch Ophthalmol. 1980 Sep;98(9):1637-8
7425927